Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial.
Emily WestMarius ZeebChristina GrubeHerbert KusterKatrin WannerThomas ScheierKathrin NeumannLisa JörimannBenjamin HampelKarin J MetznerRoger D KouyosDominique L BraunHuldrych F GünthardPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
NCT02551523.
Keyphrases
- antiretroviral therapy
- hiv infected
- end stage renal disease
- hiv infected patients
- human immunodeficiency virus
- hiv positive
- ejection fraction
- newly diagnosed
- hiv aids
- chronic kidney disease
- sars cov
- prognostic factors
- clinical trial
- randomized controlled trial
- patient reported outcomes
- patient reported
- south africa